Efficacy and safety of budesonide /formeterol inhalation in asthma patients with high fractional exhaled NO.

Efficacy and safety of budesonide /formeterol inhalation in asthma patients with high fractional exhaled NO. - Efficacy and safety of budesonide /formeterol inhalation in asthma patients with high fractional exhaled NO.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003735

Enrollment

Registered

2010-06-14

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Add inhaled budesonide/ formoterol twice daily to the current medication for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In patients with bronchial asthma, all of the following criteria are required for enrollment: 1) age;20 years or more 2) written informed consent from the patients 3) FeNO>=20ppb 4) can visit hospital for 3months

Exclusion criteria

Exclusion criteria: 1) have hypersensitivity with budesonide 2) have any severe complications 3) use of oral corticosteroids or systemic rescue medication 4) physician decided the patient is unsuitable for enrollment

Design outcomes

Primary

Measure	Time frame
Pulmonary function levels at 0, 4, 12 weeks. Fractional exhaled nitric oxide levels at 0, 4, 12 weeks. Values of impulse oscillometry at 0, 4, 12 weeks Adverse events	—

Secondary

Measure	Time frame
Exacerbations during 12weeks	—

Countries

Japan

Contacts

Public ContactSusumu Iwata

Komaki City Hospital department of respiratory medicine

sin@komakihp.gr.jp0568764131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026